

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 June 2025 (26.06.2025)



(10) International Publication Number
WO 2025/133700 A8



(51) International Patent Classification:

C07K 16/40 (2006.01) A61P 25/16 (2006.01)
A61P 25/14 (2006.01)

(21) International Application Number:

PCT/IB2024/000732

(22) International Filing Date:

20 December 2024 (20.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20230101061 20 December 2023 (20.12.2023) GR
2400120.8 04 January 2024 (04.01.2024) GB

(71) Applicant: **ALCHEMAB THERAPEUTICS LTD**

[GB/GB]; East Side Office 1.02, Kings Cross, London N1C
4AX (GB).

(72) Inventors: **GASPARIUNAS, Aretas**; c/o Alchemab Ther-

apeutics Ltd, East Side Office 1.02, Kings Cross, London
N1C 4AX (GB). **MASON, Ashely, Jane**; c/o Alchemab
Therapeutics Ltd, East Side Office 1.02, Kings Cross, Lon-

don N1C 4AX (GB). **FINCH, Donna**; c/o Alchemab Ther-
apeutics Ltd, East Side Office 1.02, Kings Cross, London
N1C 4AX (GB). **LEWIS, Giles**; c/o Alchemab Therapeu-
tics Ltd, East Side Office 1.02, Kings Cross, London N1C
4AX (GB). **PEDIADITAKIS, Iosif**; c/o Alchemab Ther-
apeutics Ltd, East Side Office 1.02, Kings Cross, Lon-
don N1C 4AX (GB). **DIAS DO NASCIMENTO, Jorge,**
Norman; c/o Alchemab Therapeutics Ltd, East Side Of-
fice 1.02, Kings Cross, London N1C 4AX (GB). **SIDOR,**
Michelle; c/o Alchemab Therapeutics Ltd, East Side Office
1.02, Kings Cross, London N1C 4AX (GB). **SNUDDEN,**
Olivia; c/o Alchemab Therapeutics Ltd, East Side Office
1.02, Kings Cross, London N1C 4AX (GB). **KOLASINS-**
KA-ZWIERZ, Paulina, Maria; c/o Alchemab Therapeu-
tics Ltd, East Side Office 1.02, Kings Cross, London N1C
4AX (GB). **YORUCU, Selda**; c/o Alchemab Therapeutics
Ltd, East Side Office 1.02, Kings Cross, London N1C 4AX
(GB).

(74) Agent: **MEWBURN ELLIS LLP**; Aurora Building, Coun-
terslip, Bristol BS1 6BX (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,

(54) Title: ANTI-15-PGDH ANTIBODIES




Fig. 14A

(57) Abstract: Isolated antibodies which bind and inhibit 15-PGDH protein are described. Related nucleic acids, cells and therapeutic uses are also described.

WO 2025/133700 A8

[Continued on next page]

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(88) Date of publication of the international search report:

31 July 2025 (31.07.2025)

(48) Date of publication of this corrected version:

28 August 2025 (28.08.2025)

(15) Information about Correction:

see Notice of 28 August 2025 (28.08.2025)